A Maresta

Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.

A Maresta, Marco Balducelli, Luca Cantini et al. · Circulation · 1994 · 151 citations · Full text

Medicine, Cardiology, Pharmacology +17

Long-Term Safety and Efficacy of Drug-Eluting Stents

Antonío Marzocchi, Francesco Saia, Giancarlo Piovaccari et al. · Circulation · 2007 · 145 citations · Full text

Medicine, Cardiology, Internal Medicine +16

Single or multivessel percutaneous coronary intervention in ST‐elevation myocardial infarction patients

Elisabetta Varani, Marco Balducelli, Matteo Aquilina et al. · Catheterization and Cardiovascular Interventions · 2008 · 107 citations · Full text

Medicine, Cardiology, Surgery +10

Two-Year Clinical Outcomes With Drug-Eluting Stents for Diabetic Patients With De Novo Coronary Lesions

Paolo Ortolani, Marco Balducelli, Paolo Marzaroli et al. · Circulation · 2008 · 69 citations

Medicine, Cardiology, Internal Medicine +13

Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: Main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT)

A Maresta, Marco Balduccelli, Elisabetta Varani et al. · American Heart Journal · 2002 · 54 citations

Medicine, Cardiology, Surgery +17